Selected For Oral Presentation: Overall Survival, Progression-Free Survival, and Quality of Life Updates from the NETTER-1 Study : 177Lu-Dotatate Vs. High Dose Octreotide In Progressive Midgut Neuroendocrine Tumors

Strosberg, J. (author)

H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

Wolin, E. (author)

Montefiore Einstein Ctr Canc Care, Bronx, NY USA

Chasen, B. (author)

Univ Texas MD Anderson Canc Ctr, Houston, TX USA

show more...

Kulke, M. (author)

Dana Farber Canc Inst, Boston, MA USA

Bushnell, D. (author)

Univ Iowa, Iowa City, IA USA

Caplin, M. (author)

Royal Free Hosp, London, England

Baum, R. P. (author)

Zent Klin, Bad Berka, Germany

Hobday, T. (author)

Mayo Clin, Coll Med, Rochester, NY USA

Hendifar, A. (author)

Cedars Sinai Med Ctr, Los Angeles, CA USA

Öberg, Kjell, 1946- (author)

Uppsala universitet,Endokrin tumörbiologi

Ruszniewski, P. (author)

Hop Beaujon, Clichy, France; Paris Diderot Univ, Clichy, France

Krenning, E. (author)

Erasmus MC, Rotterdam, Netherlands

show less...

 (creator_code:org_t)

2018-03-09

2018

English.

In: Neuroendocrinology. - : KARGER. - 0028-3835 .- 1423-0194. ; 106:Supplement: 1, s. 260-260

Related links:

https://www.karger.c...

show more...

https://urn.kb.se/re...

https://doi.org/10.1...

show less...

• Journal article (other academic/artistic)